Payment overview · 2025
General Payments
$188.91
10 reported records · 5 companies
Healthcare provider profile · identity verified
Robert N. Baskin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PLANT CITY, FL · NPI 1841252061
Verified facts
What the public records show
CMS Open Payments records show Robert N. Baskin, M.D. received $188.91 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.82 | 34.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.55 | 27.8% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.22 | 13.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.26 | 12.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.06 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.91 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.55 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.14 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 732 | 96 |
| Eliquis | Apixaban | 724 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 107 |
| Furosemide | Furosemide | 464 | 73 |
| Gabapentin | Gabapentin | 430 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 350 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 330 | 69 |
| Losartan Potassium | Losartan Potassium | 285 | 62 |
| Memantine Hcl | Memantine Hcl | 242 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 74 |
| Potassium Chloride | Potassium Chloride | 237 | 56 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 220 | 16 |
| Carvedilol | Carvedilol | 218 | 48 |
| Lisinopril | Lisinopril | 212 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 41 |
| Metformin Hcl | Metformin Hcl | 196 | 39 |
| Divalproex Sodium | Divalproex Sodium | 192 | 42 |
| Donepezil Hcl | Donepezil Hcl | 190 | 34 |
| Buspirone Hcl | Buspirone Hcl | 173 | 40 |
| Jardiance | Empagliflozin | 166 | 21 |
| Simvastatin | Simvastatin | 159 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 42 |
| Trazodone Hcl | Trazodone Hcl | 154 | 44 |
| Prednisone | Prednisone | 148 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 41 |
| Sertraline Hcl | Sertraline Hcl | 135 | 42 |
| Mupirocin | Mupirocin | 132 | 44 |
| Tramadol Hcl | Tramadol Hcl | 131 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 30 |
| Mirtazapine | Mirtazapine | 125 | 30 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 118 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 112 | 24 |
| Latanoprost | Latanoprost | 105 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 27 |
| Finasteride | Finasteride | 94 | 14 |
| Nifedipine Er | Nifedipine | 94 | 22 |
| Allopurinol | Allopurinol | 91 | 21 |
| Lorazepam | Lorazepam | 90 | 26 |
| Baclofen | Baclofen | 88 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 33 |
| Lactulose | Lactulose | 83 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 11 |
| Bumetanide | Bumetanide | 76 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 74 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 72 | 13 |
| Levofloxacin | Levofloxacin | 72 | 38 |
| Spironolactone | Spironolactone | 72 | 20 |
| Alprazolam | Alprazolam | 69 | 17 |
| Azithromycin | Azithromycin | 69 | 57 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 45 |
| Montelukast Sodium | Montelukast Sodium | 69 | 20 |
| Tradjenta | Linagliptin | 69 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 55 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 40 |
| Methenamine Hippurate | Methenamine Hippurate | 65 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 12 |
| Omeprazole | Omeprazole | 60 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 19 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 20 |
| Novolog | Insulin Aspart | 54 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 51 | 28 |
| Famotidine | Famotidine | 51 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 15 |
| Sucralfate | Sucralfate | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 16 |
| Santyl | Collagenase Clostridium Hist. | 46 | 16 |
| Insulin Aspart | Insulin Aspart | 45 | 18 |
| Albuterol Sulfate | Albuterol Sulfate | 44 | suppressed |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 39 |
| Nystatin | Nystatin | 44 | 31 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 26 |
| Cephalexin | Cephalexin | 43 | 30 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | 15 |
| Atenolol | Atenolol | 42 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 42 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 42 | 20 |
| Trimethoprim | Trimethoprim | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | 15 |
| Glipizide | Glipizide | 39 | 12 |
| Clonazepam | Clonazepam | 38 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Metolazone | Metolazone | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 25 |
| Amoxicillin | Amoxicillin | 36 | 22 |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Digoxin | Digoxin | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 19 |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 22 |
| Nystop | Nystatin | 32 | 19 |
| Clonidine Hcl | Clonidine Hcl | 31 | 11 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Enulose | Lactulose | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 27 | suppressed |
| Calcium Acetate | Calcium Acetate | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 15 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Alogliptin | Alogliptin Benzoate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Acetic Acid | Acetic Acid | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 11 |
| Humalog | Insulin Lispro | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 13 |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Linezolid | Linezolid | 16 | suppressed |
| Meropenem | Meropenem | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.91 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, REPATHA, TRELEGY ELLIPTA, WATCHMAN FLX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error